Blog
RSS FeedPosted by Michael Wonder on 22 Mar 2016
Confirmed 1 April 2016 prices resulting from 2016 April Cycle of Price Disclosure
22 March 2016 - Confirmed 1 April 2016 prices resulting from the 2016 April Cycle of Price Disclosure have now been ...
Posted by Michael Wonder on 21 Mar 2016
Call for NZ Government to fund HPV vaccine for boys
20 March 2016 - Throat-cancer patient Grant Munro paid for his son to be vaccinated against the sexually-transmitted HPV virus because ...
Posted by Michael Wonder on 21 Mar 2016
NICE recommends abiraterone acetate for prostate cancer
21 March 2016 - NICE has issued final guidance recommending abiraterone (marketed as Zytiga by Janssen) for some prostate cancer patients*. ...
Posted by Michael Wonder on 21 Mar 2016
NICE confirms support for Novartis' heart drug Entresto
20 March 2016 - Cost regulators for the National Health Service in England and Wales have reiterated their support for the ...
Posted by Michael Wonder on 20 Mar 2016
PBAC Drug Utilisation Sub Committee outcome statement
18 March 2016 - The outcome statement from the February 2016 PBAC Drug Utilisation Sub Committee (DUSC) meeting is now available ...
Posted by Michael Wonder on 20 Mar 2016
Crossing the line: NICE’s value for money threshold
9 March 2016 - John Appleby explains the link between the NICE threshold and the NHS budget and considers whether it ...
Posted by Michael Wonder on 19 Mar 2016
SMC announces more forthcoming submissions
18 March 2016 - The SMC has announced forthcoming submissions for the following medicines: carfilzomib (Kyprolis), dasatinib monohydrate (Sprycel), emtricitabine with ...
Posted by Michael Wonder on 19 Mar 2016
Additional public summary documents - PBAC November 2015 meeting
18 March 2016 - Additional public summary documents from the PBAC November 2015 meeting are now available on the PBS website. ...
Posted by Michael Wonder on 19 Mar 2016
Addendum on regorafenib in metastatic colorectal cancer: added benefit no longer proven
17 March 2016 - The drug manufacturer presented further analyses; the additional disadvantages outweigh the survival advantage. ...
Posted by Michael Wonder on 19 Mar 2016
Dabrafenib/trametinib: considerable added benefit for men with advanced melanoma
17 March 2016 - Study data subsequently submitted allow quantification / still major added benefit for women. ...
Posted by Michael Wonder on 17 Mar 2016
Decision to list galsulfase (Naglazyme) for mucopolysaccharidosis (MPS) VI
17 March 2016 - PHARMAC is pleased to announce the approval of an agreement with BioMarin Pharmaceutical Australia Pty Ltd to ...
Posted by Michael Wonder on 17 Mar 2016
Call for patient input on a submission from UCB for brivaracetam
17 March 2016 - CADTH has received notice of a pending submission from UCB for brivaracetam for the treatment of patients ...
Posted by Michael Wonder on 16 Mar 2016
Cobimetinib in advanced melanoma with BRAF V600 mutation: little additional value says Germany's IQWiG
15 March 2016 - TheIQWiG found more positive and negative patient-relevant outcomes, which tend to cancel each other. There ...
Posted by Michael Wonder on 16 Mar 2016
NICE consults on ‘no’ recommendation for skin cancer drug talimogene laherparepvec
16 March 2016 - NICE has today issued draft guidance not recommending talimogene laherparepvec (Imlygic, Amgen) as an option for people ...
Posted by Michael Wonder on 16 Mar 2016
Faster access to effective cancer treatments through new Cancer Drugs Fund
16 March 2016 - Proposals will see new clinically and cost effective cancer drugs approved for use on the NHS earlier ...